Sudden cardiac death is a major public health problem, affecting 500,000 patients in the
United States annually. An implantable cardioverter-defibrillator (ICD) can terminate …

Background: The PRAETORIAN trial (A Prospective, Randomized Comparison of
Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) showed …

Background Implantable cardioverter–defibrillators (ICDs) are battery-powered implantable
devices that monitor heart rhythm and deliver therapy in the form of either electric shock or …

Objectives: Our purpose was to demonstrate that strategically chosen implantable
cardioverter-defibrillator (ICD) ventricular tachycardia (VT) or ventricular fibrillation (VF) …

Background Although the implantable cardioverter defibrillator is successful in terminating
life threatening arrhythmias, it might give unwanted shocks in the last phase of life if not …

Background—Several trials have demonstrated improved survival with implantable
cardioverter-defibrillator (ICD) therapy. The cause and nature of death in the ICD population …

The implantable cardioverter defibrillator (ICD) has been a major advance in the treatment of
malignant ventricular arrhythmias and prevention of sudden cardiac death. 1, 2 Although …

Background Patients with atrial fibrillation (AF) or congestive heart failure (CHF) are more
vulnerable to inappropriate shocks from implantable cardioverter-defibrillators (ICDs), but …

705 use of antiarrhythmic drugs in some patients sometimes becomes necessary and may
be beneficial. The usefulness of this approach is reflected in the fact that upward of 70% of …

Aims Strategically chosen ventricular tachycardia (VT)/ventricular fibrillation (VF) detection
and therapy parameters aimed at reducing shock deliveries were proven effective in studies …